Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633817 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL30510296 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL29400893 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL120595 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL120592 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL118926 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL30688517 | 0.95 | ITGB3 (0.44) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25182226 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25182320 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BFABP5FABP7PPARG | |
| SCHEMBL25356271 | 0.93 | PPARG (0.43) | ITGB3ITGA2BFABP5FABP7PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114085269-B | All-solid-phase synthesis method of Hoshinoamide A | 滁州学院 | 2024-01-30 | — | — | CN | claimed |
| CN-114085269-A | All-solid-phase synthesis method of Hoshinoamide A | 滁州学院 | 2022-02-25 | — | — | CN | claimed |
| US-20250320248-A1 | MENAQUINONE-BINDING COMPOUNDS AND METHODS OF USE THEREOF | UNIV ROCKEFELLER (US) | 2025-10-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023070085-A2 | MENAQUINONE-BINDING COMPOUNDS AND METHODS OF USE THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-114085269-A | All-solid-phase synthesis method of Hoshinoamide A | 滁州学院 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | ITGB3 3132/4885ITGA2B 3367/4885FABP5 4000/4885 |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | ITGB3 3132/4885ITGA2B 3367/4885FABP5 4000/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ITGB3 4849/4885ITGA2B 4821/4885FABP5 4094/4885 |
| US-20250320248-A1 | MENAQUINONE-BINDING COMPOUNDS AND METHODS OF USE THEREOF | PROC, NQO1, MMAB | ITGB3 1091/4885ITGA2B 809/4885FABP5 487/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | ITGB3 3132/4885ITGA2B 3367/4885FABP5 4000/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ITGB3 4849/4885ITGA2B 4821/4885FABP5 4094/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | ITGB3 4856/4885ITGA2B 4718/4885FABP5 4631/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ITGB3 4856/4885ITGA2B 4718/4885FABP5 4631/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ITGB3 4856/4885ITGA2B 4718/4885FABP5 4631/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ITGB3 4849/4885ITGA2B 4821/4885FABP5 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.